11,900 Shares in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,900 shares of the company’s stock, valued at approximately $175,000.

Several other hedge funds have also recently added to or reduced their stakes in AMLX. Premier Path Wealth Partners LLC acquired a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth $298,000. Graham Capital Management L.P. grew its holdings in Amylyx Pharmaceuticals by 84.1% during the 3rd quarter. Graham Capital Management L.P. now owns 56,241 shares of the company’s stock worth $1,030,000 after acquiring an additional 25,689 shares during the period. Rafferty Asset Management LLC bought a new position in shares of Amylyx Pharmaceuticals in the 3rd quarter worth about $207,000. Qube Research & Technologies Ltd raised its position in shares of Amylyx Pharmaceuticals by 31.0% in the 3rd quarter. Qube Research & Technologies Ltd now owns 162,710 shares of the company’s stock worth $2,979,000 after acquiring an additional 38,530 shares in the last quarter. Finally, abrdn plc acquired a new position in shares of Amylyx Pharmaceuticals in the 4th quarter valued at about $2,878,000. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX opened at $2.03 on Friday. The company has a market capitalization of $138.06 million, a P/E ratio of 2.90 and a beta of -0.68. The company’s 50-day moving average is $5.77 and its 200 day moving average is $11.90. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.70 and a fifty-two week high of $30.50.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, February 22nd. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.03. The firm had revenue of $108.45 million for the quarter, compared to analyst estimates of $106.40 million. Amylyx Pharmaceuticals had a return on equity of 12.39% and a net margin of 12.94%. During the same period in the previous year, the company posted ($0.65) earnings per share. As a group, research analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.01 earnings per share for the current year.

Insider Activity

In other news, insider Gina Mazzariello sold 2,838 shares of the company’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $18.76, for a total transaction of $53,240.88. Following the sale, the insider now directly owns 46,245 shares in the company, valued at $867,556.20. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Gina Mazzariello sold 2,838 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $18.76, for a total value of $53,240.88. Following the sale, the insider now directly owns 46,245 shares of the company’s stock, valued at $867,556.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James M. Frates sold 1,792 shares of Amylyx Pharmaceuticals stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total transaction of $33,564.16. Following the sale, the chief financial officer now directly owns 134,784 shares of the company’s stock, valued at $2,524,504.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,305 shares of company stock worth $193,098. 11.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on AMLX. The Goldman Sachs Group reiterated a “neutral” rating on shares of Amylyx Pharmaceuticals in a report on Friday, March 8th. SVB Leerink downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, March 11th. Robert W. Baird lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Monday, March 11th. Evercore ISI reaffirmed an “in-line” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th. Finally, Leerink Partnrs cut shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, March 11th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Amylyx Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $32.67.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.